North America Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet’s Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, Peripheral Arterial Tonometry (PAT), Venous Occlusion Pletismography, Circulating Markers, and Others)], and End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others)
The North America endothelial dysfunction market is expected to grow from US$ 951.83 million in 2022 to US$ 1,247.30 million by 2028. It is estimated to grow at a CAGR of 4.6% from 2022 to 2028.
Increasing Incidences of Cardiovascular Diseases Fuels North America Endothelial Dysfunction Market
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are among the leading causes of death worldwide, and ~30 million people experience a stroke each year. CVDs include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and coronary artery disease (CAD). CAD is the most common disease among all cardiovascular diseases, and it is characterized by the accumulation of lipids and immune cells in the subendothelial space of the coronary arteries or atherosclerosis. It involves the inflammatory response of the vascular endothelium. CAD is characterized by ischemia, hypoxia, or necrosis of the myocardium resulting from narrowing, spasm, or obstruction of the coronary artery lumen by atherosclerosis. It has become the leading cause of death worldwide. According to the Centers for Disease Control and Prevention (CDC), over 60 million women (44%) in the US suffer from some form of heart disease. Heart disease is the leading cause of death among women in the US and can affect women of any age. In 2021, it caused 310,661 deaths among women, i.e., nearly one in five female deaths.
According to the American Heart Association, almost half of all adults in the US suffer from a type of CVD. Over 130 million people, i.e., 45.1% of the US population, are projected to suffer from a type of CVD by 2035. Therefore, the high prevalence of cardiovascular diseases due to endothelial dysfunction drives the market.
North America Endothelial Dysfunction Market Overview
The North American endothelial dysfunction market is analyzed on the basis of three major countries: the US, Canada, and Mexico. The market expansion in the region can be attributed to an increase in the incidence of cardiac diseases and rising investments in cardiology informatics. The US holds the largest size of the endothelial dysfunction market in North America owing to factors such as the increasing burden of CAD, established healthcare infrastructure, and R&D activities undertaken to develop advanced endothelial dysfunction drugs and devices.
North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
North America Endothelial Dysfunction Market Segmentation
The North America endothelial dysfunction market is segmented into cause, test type, end user, and country.
Based on cause, the North America endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment registered the largest North America endothelial dysfunction market share in 2022.
Based on test type, the North America endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger North America endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the North America endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest North America endothelial dysfunction market share in 2022.
Based on country, the North America endothelial dysfunction market is segmented into the US, Canada, and Mexico. The US dominated the North America endothelial dysfunction market in 2022.
ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.
Increasing Incidences of Cardiovascular Diseases Fuels North America Endothelial Dysfunction Market
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are among the leading causes of death worldwide, and ~30 million people experience a stroke each year. CVDs include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and coronary artery disease (CAD). CAD is the most common disease among all cardiovascular diseases, and it is characterized by the accumulation of lipids and immune cells in the subendothelial space of the coronary arteries or atherosclerosis. It involves the inflammatory response of the vascular endothelium. CAD is characterized by ischemia, hypoxia, or necrosis of the myocardium resulting from narrowing, spasm, or obstruction of the coronary artery lumen by atherosclerosis. It has become the leading cause of death worldwide. According to the Centers for Disease Control and Prevention (CDC), over 60 million women (44%) in the US suffer from some form of heart disease. Heart disease is the leading cause of death among women in the US and can affect women of any age. In 2021, it caused 310,661 deaths among women, i.e., nearly one in five female deaths.
According to the American Heart Association, almost half of all adults in the US suffer from a type of CVD. Over 130 million people, i.e., 45.1% of the US population, are projected to suffer from a type of CVD by 2035. Therefore, the high prevalence of cardiovascular diseases due to endothelial dysfunction drives the market.
North America Endothelial Dysfunction Market Overview
The North American endothelial dysfunction market is analyzed on the basis of three major countries: the US, Canada, and Mexico. The market expansion in the region can be attributed to an increase in the incidence of cardiac diseases and rising investments in cardiology informatics. The US holds the largest size of the endothelial dysfunction market in North America owing to factors such as the increasing burden of CAD, established healthcare infrastructure, and R&D activities undertaken to develop advanced endothelial dysfunction drugs and devices.
North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
North America Endothelial Dysfunction Market Segmentation
The North America endothelial dysfunction market is segmented into cause, test type, end user, and country.
Based on cause, the North America endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment registered the largest North America endothelial dysfunction market share in 2022.
Based on test type, the North America endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger North America endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the North America endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest North America endothelial dysfunction market share in 2022.
Based on country, the North America endothelial dysfunction market is segmented into the US, Canada, and Mexico. The US dominated the North America endothelial dysfunction market in 2022.
ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.
1. INTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Endothelial Dysfunction Market - by Cause
1.3.2 North America Endothelial Dysfunction Market - by Test Type
1.3.3 North America Endothelial Dysfunction Market - by End User
1.3.4 North America Endothelial Dysfunction Market - by Country
2. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET - KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET - MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Expert Opinion
5. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Incidences of Cardiovascular Diseases
5.1.2 Rising Incidences of High Cholesterol, Diabetes And Obesity
5.2 Market Restraints
5.2.1 Disadvantages Associated with the Techniques for Screening of Endothelial Dysfunction
5.3 Market Opportunities
5.3.1 Rising Usage of Novel Biomarkers and Therapeutic Strategies
5.4 Future Trends
5.4.1 Use of Noninvasive Methods to Assess Endothelial Dysfunction
5.5 Impact Analysis
6. ENDOTHELIAL DYSFUNCTION MARKET - NORTH AMERICA ANALYSIS
6.1 North America Endothelial Dysfunction Market Revenue Forecast and Analysis
7. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET ANALYSIS - BY CAUSE
7.1 Overview
7.2 North America Endothelial Dysfunction Market, By Cause, 2022 & 2028 (%)
7.3 Hypertension
7.3.1 Overview
7.3.2 Hypertension: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.5 Hypercholestrolaemia
7.5.1 Overview
7.5.2 Hypercholestrolaemia: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.6 Behcet’s Disease
7.6.1 Overview
7.6.2 Behcet’s Disease: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.7 Obesity
7.7.1 Overview
7.7.2 Obesity: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET ANALYSIS - BY TEST TYPE
8.1 Overview
8.2 North America Endothelial Dysfunction Market, By Test Type, 2022 & 2028 (%)
8.3 Invasive Tests
8.3.1 Overview
8.3.2 Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4 Non-Invasive Tests
8.4.1 Overview
8.4.2 Non-Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.3 Flow Mediated Dilatory
8.4.3.1 Overview
8.4.3.2 Flow Mediated Dilatory: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.4 Venous Occlusion Plethysmography
8.4.4.1 Overview
8.4.4.2 Venous Occlusion Plethysmography: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.5 Peripheral Arterial Tonometry (PAT)
8.4.5.1 Overview
8.4.5.2 Peripheral Arterial Tonometry (PAT): North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.6 Circulating Markers
8.4.6.1 Overview
8.4.6.2 Circulating Markers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.7 Others
8.4.7.1 Overview
8.4.7.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET ANALYSIS - BY END USER
9.1 Overview
9.2 North America Endothelial Dysfunction Market, By End User, 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostics Centers
9.4.1 Overview
9.4.2 Diagnostics Centers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.5 Clinics
9.5.1 Overview
9.5.2 Clinics: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
10. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET - REVENUE AND FORECAST TO 2028 - COUNTRY ANALYSIS
10.1 North America: Endothelial Dysfunction Market
10.1.1 Overview
10.1.1.1 US: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 US: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.3 US: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.1.4 US: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
10.1.1.1.4.1 US: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.5 US: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
10.1.1.2 Canada: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Canada: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 Canada: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.2.4 Canada: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
10.1.1.2.4.1 Canada: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.5 Canada: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
10.1.1.3 Mexico: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Mexico: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 Mexico: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.3.4 Mexico: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
10.1.1.3.4.1 Mexico: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.5 Mexico: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
11. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET-INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in the Endothelial Dysfunction Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 ZOLL Medical Corp
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Lawrence Berkeley National Laboratory
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Endothelix Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Perimed AB
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6
12.4.7 Key Developments
12.5 SMART Medical Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Everist Health Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Medizinische Messtechnik GmbH
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. APPENDIX
13.1 About The Insight Partners
13.2 Glossary of Terms
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Endothelial Dysfunction Market - by Cause
1.3.2 North America Endothelial Dysfunction Market - by Test Type
1.3.3 North America Endothelial Dysfunction Market - by End User
1.3.4 North America Endothelial Dysfunction Market - by Country
2. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET - KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET - MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Expert Opinion
5. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Incidences of Cardiovascular Diseases
5.1.2 Rising Incidences of High Cholesterol, Diabetes And Obesity
5.2 Market Restraints
5.2.1 Disadvantages Associated with the Techniques for Screening of Endothelial Dysfunction
5.3 Market Opportunities
5.3.1 Rising Usage of Novel Biomarkers and Therapeutic Strategies
5.4 Future Trends
5.4.1 Use of Noninvasive Methods to Assess Endothelial Dysfunction
5.5 Impact Analysis
6. ENDOTHELIAL DYSFUNCTION MARKET - NORTH AMERICA ANALYSIS
6.1 North America Endothelial Dysfunction Market Revenue Forecast and Analysis
7. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET ANALYSIS - BY CAUSE
7.1 Overview
7.2 North America Endothelial Dysfunction Market, By Cause, 2022 & 2028 (%)
7.3 Hypertension
7.3.1 Overview
7.3.2 Hypertension: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.5 Hypercholestrolaemia
7.5.1 Overview
7.5.2 Hypercholestrolaemia: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.6 Behcet’s Disease
7.6.1 Overview
7.6.2 Behcet’s Disease: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.7 Obesity
7.7.1 Overview
7.7.2 Obesity: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET ANALYSIS - BY TEST TYPE
8.1 Overview
8.2 North America Endothelial Dysfunction Market, By Test Type, 2022 & 2028 (%)
8.3 Invasive Tests
8.3.1 Overview
8.3.2 Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4 Non-Invasive Tests
8.4.1 Overview
8.4.2 Non-Invasive Tests: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.3 Flow Mediated Dilatory
8.4.3.1 Overview
8.4.3.2 Flow Mediated Dilatory: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.4 Venous Occlusion Plethysmography
8.4.4.1 Overview
8.4.4.2 Venous Occlusion Plethysmography: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.5 Peripheral Arterial Tonometry (PAT)
8.4.5.1 Overview
8.4.5.2 Peripheral Arterial Tonometry (PAT): North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.6 Circulating Markers
8.4.6.1 Overview
8.4.6.2 Circulating Markers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
8.4.7 Others
8.4.7.1 Overview
8.4.7.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET ANALYSIS - BY END USER
9.1 Overview
9.2 North America Endothelial Dysfunction Market, By End User, 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostics Centers
9.4.1 Overview
9.4.2 Diagnostics Centers: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.5 Clinics
9.5.1 Overview
9.5.2 Clinics: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
10. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET - REVENUE AND FORECAST TO 2028 - COUNTRY ANALYSIS
10.1 North America: Endothelial Dysfunction Market
10.1.1 Overview
10.1.1.1 US: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 US: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.3 US: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.1.4 US: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
10.1.1.1.4.1 US: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.5 US: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
10.1.1.2 Canada: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Canada: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 Canada: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.2.4 Canada: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
10.1.1.2.4.1 Canada: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.5 Canada: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
10.1.1.3 Mexico: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 Mexico: Endothelial Dysfunction Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 Mexico: Endothelial Dysfunction Market, by Cause, 2020-2028 (US$ Million)
10.1.1.3.4 Mexico: Endothelial Dysfunction Market, by Test Type - 2020-2028 (US$ Million)
10.1.1.3.4.1 Mexico: Endothelial Dysfunction Market, by Non-Invasive Tests - Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.5 Mexico: Endothelial Dysfunction Market, by End User 2020-2028 (US$ Million)
11. NORTH AMERICA ENDOTHELIAL DYSFUNCTION MARKET-INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in the Endothelial Dysfunction Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 ZOLL Medical Corp
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Lawrence Berkeley National Laboratory
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Endothelix Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Perimed AB
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6
12.4.7 Key Developments
12.5 SMART Medical Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Everist Health Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Medizinische Messtechnik GmbH
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. APPENDIX
13.1 About The Insight Partners
13.2 Glossary of Terms
